BMC Anesthesiology · 2013 · 78 citations · 15 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyAntimicrobial ResistanceCritical Care PharmacotherapyAerosol TherapyAntibiotic ResistanceAntimicrobial TherapyAerosolized AntibioticsDrug-resistant PathogensIn-hospital MortalityMicrobiologic DiagnosisMicrobiological CureMultidrug-resistant Gram-negative BacteriaPneumonia Empiric TherapyPost Hoc Subgroup Analysis
BACKGROUND: The incidence of multi-drug resistant (MDR) gram-negative (GN) organisms including Pseudomonas and Acinetobacter spp has increased in the last decade, prompting re-evaluation of colistin for the management of these infections. Aerosolized colistin as an adjunct to intravenous therapy is a current option for the management of MDR-GN pneumonia, although data supporting this practice is limited. This study evaluates the efficacy of adjunctive aerosolized colistin in combination with intravenous colistin in critically ill patients with MDR-GN pneumonia. METHODS: A retrospective multi-center cohort analysis comparing critically ill patients with MDR-GN pneumonia who received intravenous colistin (IV) alone or in combination with adjunctive aerosolized colistin (IV/AER) with a primary endpoint of clinical cure at the end of colistin therapy. Secondary endpoints included microbiologic cure, duration of mechanical ventilation, length of stay, and hospital mortality. A post-hoc subgroup analysis was performed for patients with high quality cultures used for diagnosis of MDR-GN pneumonia. Dichotomous data were compared using Fisher's exact test while the student's t-test or Mann-Whitney U test were used for continuous variables. RESULTS: Ninety-five patients met criteria for evaluation with 51 patients receiving IV and 44 receiving IV/AER. Baseline characteristics were similar between the two groups. Twenty patients (39.2%) receiving IV and 24 (54.5%) receiving IV/AER achieved clinical cure (p = 0.135). There was no difference in microbiologic cure rates between the IV and IV/AER colistin groups (40.7vs. 44.4%, p = 0.805). The IV group demonstrated a trend towards higher pneumonia attributable mortality (70.4 vs. 40%, p = 0.055). In the subgroup analysis of patients with high quality respiratory cultures, there was a significantly lower clinical cure rate for those in the IV group as compared to the IV/AER group (31.3 vs. 57.1%, p = 0.033). CONCLUSIONS: Addition of aerosolized colistin to IV colistin may improve clinical cure and mortality for patients with MDR-GN pneumonia. Larger, prospective trials are warranted to confirm the benefit of adjunctive aerosolized colistin in critically ill patients with MDR-GN pneumonia.
15
Teresa Horan, Mary Andrus, Margaret A. Dudeck · American Journal of Infection Control · 2008 · 6.6K citations
Public Health, Infectious Disease Control, Infectious Diseases +16
Paul Dennesen, Alphons G.H. Kessels, Graham Ramsay et al. · American Journal of Respiratory and Critical Care Medicine · 2001 · 341 citations
Mark E. Jones, Deborah C. Draghi, Clyde Thornsberry et al. · Annals of Clinical Microbiology and Antimicrobials · 2004 · 272 citations · Full text
Funda Timurkaynak, Füsun Can, Özlem Kurt Azap et al. · International Journal of Antimicrobial Agents · 2006 · 218 citations
Argyris Michalopoulos, Sofia K. Kasiakou, Zefi Mastora et al. · Critical Care · 2004 · 207 citations · Full text